Alexander Karatzanis1, Alkiviadis Chatzidakis1, Athanasia Milioni1, Stephan Vlaminck2, Hideyuki Kawauchi3, Stylianos Velegrakis1, Emmanuel Prokopakis4,5. 1. Department of Otorhinolaryngology, School of Medicine, University of Crete, Heraklion, Crete, Greece. 2. Department of Otorhinolaryngology, St. Jan General Hospital, Bruges, Belgium. 3. Department of Otorhinolaryngology, School of Medicine, University of Shimane, Shimane, Japan. 4. Department of Otorhinolaryngology, School of Medicine, University of Crete, Heraklion, Crete, Greece. eprokopakis@gmail.com. 5. Department of Otorhinolaryngology, University Hospital of Crete, University avenue, A Building 3rd Floor, 71110, Heraklion, Crete, Greece. eprokopakis@gmail.com.
Abstract
PURPOSE OF REVIEW: Exogenously administered corticosteroids are widely used today in the field of rhinology. Allergic rhinitis (AR), non-allergic rhinitis (NAR), acute rhinosinusitis (ARS), chronic rhinosinusitis with (CRSwNP) and without (CRSsNP) nasal polyps, and autoimmune disorders with nasal manifestations are common diseases treated effectively with intranasal and oral glucocorticoids. We focus on physiological pathways, therapeutic benefits, indications, contra-indications, and side effects of glucocorticoid utilization in the treatment of rhinologic disorders such as AR, NAR, ARS, CRSsNP, and CRSwNP. RECENT FINDINGS: Second-generation intranasal steroid (INS) agents have pharmacokinetic characteristics that minimize their systemic bioavailability, resulting in minimum risk for systemic adverse events. Several studies have demonstrated the symptomatic efficacy of both intranasal and oral corticosteroids in ARS. Moreover, intranasal and systemic steroid administration has been repeatedly proven beneficial in the conservative and perioperative management of CRSwNP. For patients with AR, there is no need for oral steroids, with the exception of severe cases, as there is lack of superiority to INS. SCUAD patients challenge currently available treatment schemes, underlining the importance of research in the field. Corticosteroids' effectiveness in the treatment of various rhinologic disorders is indisputable. However, their characteristics, and potential side effects, make a clear consensus for utilization difficult.
PURPOSE OF REVIEW: Exogenously administered corticosteroids are widely used today in the field of rhinology. Allergic rhinitis (AR), non-allergic rhinitis (NAR), acute rhinosinusitis (ARS), chronic rhinosinusitis with (CRSwNP) and without (CRSsNP) nasal polyps, and autoimmune disorders with nasal manifestations are common diseases treated effectively with intranasal and oral glucocorticoids. We focus on physiological pathways, therapeutic benefits, indications, contra-indications, and side effects of glucocorticoid utilization in the treatment of rhinologic disorders such as AR, NAR, ARS, CRSsNP, and CRSwNP. RECENT FINDINGS: Second-generation intranasal steroid (INS) agents have pharmacokinetic characteristics that minimize their systemic bioavailability, resulting in minimum risk for systemic adverse events. Several studies have demonstrated the symptomatic efficacy of both intranasal and oral corticosteroids in ARS. Moreover, intranasal and systemic steroid administration has been repeatedly proven beneficial in the conservative and perioperative management of CRSwNP. For patients with AR, there is no need for oral steroids, with the exception of severe cases, as there is lack of superiority to INS. SCUAD patients challenge currently available treatment schemes, underlining the importance of research in the field. Corticosteroids' effectiveness in the treatment of various rhinologic disorders is indisputable. However, their characteristics, and potential side effects, make a clear consensus for utilization difficult.
Authors: Bruce G Martin; Paul H Ratner; Frank C Hampel; Charles P Andrews; Tom Toler; Wei Wu; Melissa A Faris; Edward E Philpot Journal: Allergy Asthma Proc Date: 2007 Mar-Apr Impact factor: 2.587
Authors: David C Lin; Rakesh K Chandra; Bruce K Tan; Whitney Zirkle; David B Conley; Leslie C Grammer; Robert C Kern; Robert P Schleimer; Anju T Peters Journal: Am J Rhinol Allergy Date: 2011 Jul-Aug Impact factor: 2.467
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinology Date: 2012-03 Impact factor: 3.681
Authors: J Mullol; E López; J Roca-Ferrer; A Xaubet; L Pujols; J C Fernàndez-Morata; J M Fabra; C Picado Journal: Clin Exp Allergy Date: 1997-12 Impact factor: 5.018
Authors: Karen Head; Lee Yee Chong; Claire Hopkins; Carl Philpott; Martin J Burton; Anne G M Schilder Journal: Cochrane Database Syst Rev Date: 2016-04-26
Authors: Sara Treat; Charles S Ebert; Zainab Farzal; Saikat Basu; Adam M Zanation; Brian D Thorp; Julia S Kimbell; Brent A Senior; Adam J Kimple Journal: Rhinol Online Date: 2020-11-08
Authors: Eulalia Sakano; Emanuel S C Sarinho; Alvaro A Cruz; Antonio C Pastorino; Edwin Tamashiro; Fábio Kuschnir; Fábio F M Castro; Fabrizio R Romano; Gustavo F Wandalsen; Herberto J Chong-Neto; João F de Mello; Luciana R Silva; Maria Cândida Rizzo; Mônica A M Miyake; Nelson A Rosário Filho; Norma de Paula M Rubini; Olavo Mion; Paulo A Camargos; Renato Roithmann; Ricardo N Godinho; Shirley Shizue N Pignatari; Tania Sih; Wilma T Anselmo-Lima; Dirceu Solé Journal: Braz J Otorhinolaryngol Date: 2017-11-02